These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 21997174)

  • 1. Role of adjuvant chemotherapy in patients with early stage uterine papillary serous cancer.
    Mahdavi A; Tajalli TR; Dalmar A; Vasilev SA; Lentz SE; Berman ML
    Int J Gynecol Cancer; 2011 Nov; 21(8):1436-40. PubMed ID: 21997174
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improved survival in surgical stage I patients with uterine papillary serous carcinoma (UPSC) treated with adjuvant platinum-based chemotherapy.
    Kelly MG; O'malley DM; Hui P; McAlpine J; Yu H; Rutherford TJ; Azodi M; Schwartz PE
    Gynecol Oncol; 2005 Sep; 98(3):353-9. PubMed ID: 16005947
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effective treatment of stage I uterine papillary serous carcinoma with high dose-rate vaginal apex radiation (192Ir) and chemotherapy.
    Turner BC; Knisely JP; Kacinski BM; Haffty BG; Gumbs AA; Roberts KB; Frank AH; Peschel RE; Rutherford TJ; Edraki B; Kohorn EI; Chambers SK; Schwartz PE; Wilson LD
    Int J Radiat Oncol Biol Phys; 1998 Jan; 40(1):77-84. PubMed ID: 9422561
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Platinum/taxane-based chemotherapy with or without radiation therapy favorably impacts survival outcomes in stage I uterine papillary serous carcinoma.
    Fader AN; Drake RD; O'Malley DM; Gibbons HE; Huh WK; Havrilesky LJ; Gehrig PA; Tuller E; Axtell AE; Zanotti KM;
    Cancer; 2009 May; 115(10):2119-27. PubMed ID: 19306417
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of systematic lymphadenectomy and adjuvant therapy in stage I uterine papillary serous carcinoma.
    Thomas MB; Mariani A; Cliby WA; Keeney GA; Podratz KC; Dowdy SC
    Gynecol Oncol; 2007 Nov; 107(2):186-9. PubMed ID: 17688926
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Five-year outcomes of adjuvant carboplatin/paclitaxel chemotherapy and intravaginal radiation for stage I-II papillary serous endometrial cancer.
    Kiess AP; Damast S; Makker V; Kollmeier MA; Gardner GJ; Aghajanian C; Abu-Rustum NR; Barakat RR; Alektiar KM
    Gynecol Oncol; 2012 Nov; 127(2):321-5. PubMed ID: 22850412
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of adjuvant chemotherapy versus whole abdominopelvic radiation on the survival of patients with advanced stage uterine papillary serous carcinoma.
    Hamilton CA; Cheung MK; Osann K; Balzer B; Berman ML; Husain A; Teng NN; Kapp DS; Chan JK
    Gynecol Oncol; 2006 Nov; 103(2):679-83. PubMed ID: 16793126
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The efficacy of adjuvant platinum-based chemotherapy in Stage I uterine papillary serous carcinoma (UPSC).
    Dietrich CS; Modesitt SC; DePriest PD; Ueland FR; Wilder J; Reedy MB; Pavlik EJ; Kryscio R; Cibull M; Giesler J; Manahan K; Huh W; Cohn D; Powell M; Slomovitz B; Higgins RV; Merritt W; Hunter J; Puls L; Gehrig P; van Nagell JR
    Gynecol Oncol; 2005 Dec; 99(3):557-63. PubMed ID: 16154185
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Extended surgical staging for uterine papillary serous carcinoma: survival outcome of locoregional (Stage I-III) disease.
    Bristow RE; Asrari F; Trimble EL; Montz FJ
    Gynecol Oncol; 2001 May; 81(2):279-86. PubMed ID: 11330963
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of adjuvant chemotherapy and pelvic radiation on pattern of recurrence and outcome in stage I non-invasive uterine papillary serous carcinoma. A multi-institution study.
    Mahdi H; Elshaikh MA; DeBenardo R; Munkarah A; Isrow D; Singh S; Waggoner S; Ali-Fehmi R; Morris RT; Harding J; Moslemi-Kebria M
    Gynecol Oncol; 2015 May; 137(2):239-44. PubMed ID: 25641568
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patterns of failure after the multimodality treatment of uterine papillary serous carcinoma.
    Sood BM; Jones J; Gupta S; Khabele D; Guha C; Runowicz C; Goldberg G; Fields A; Anderson P; Vikram B
    Int J Radiat Oncol Biol Phys; 2003 Sep; 57(1):208-16. PubMed ID: 12909235
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Uterine Papillary Serous Carcinoma: A Single-Institution Review of 62 Cases.
    Black C; Feng A; Bittinger S; Quinn M; Neesham D; McNally O
    Int J Gynecol Cancer; 2016 Jan; 26(1):133-40. PubMed ID: 26588230
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stage II uterine papillary serous carcinoma: Carboplatin/paclitaxel chemotherapy improves recurrence and survival outcomes.
    Fader AN; Nagel C; Axtell AE; Zanotti KM; Kelley JL; Moore KN; Secord AA; Walsh CS; Huh WK; Gehrig PA; Gibbons H; Rose PG; Havrilesky LJ; Tuller E; Drake RD; Bottsford-Miller J; O'Malley DM;
    Gynecol Oncol; 2009 Mar; 112(3):558-62. PubMed ID: 19118888
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The use of paclitaxel and platinum-based chemotherapy in uterine papillary serous carcinoma.
    Zanotti KM; Belinson JL; Kennedy AW; Webster KD; Markman M
    Gynecol Oncol; 1999 Aug; 74(2):272-7. PubMed ID: 10419744
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pilot phase II trial of radiation "sandwiched" between combination paclitaxel/platinum chemotherapy in patients with uterine papillary serous carcinoma (UPSC).
    Fields AL; Einstein MH; Novetsky AP; Gebb J; Goldberg GL
    Gynecol Oncol; 2008 Jan; 108(1):201-6. PubMed ID: 17997145
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of Chemotherapy and Radiotherapy on Management of Early Stage Clear Cell and Papillary Serous Carcinoma of the Uterus.
    Hong JC; Foote J; Broadwater G; Gaillard S; Havrilesky LJ; Chino JP
    Int J Gynecol Cancer; 2017 May; 27(4):720-729. PubMed ID: 28375927
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of early-stage uterine papillary serous carcinoma at Roswell Park Cancer Institute, 1992-2006.
    Tchabo NE; McCloskey S; Mashtare TL; Andrews C; Singh AK; Mhawech-Fauceglia P; Odunsi K; Lele S; Jaggernauth W
    Gynecol Oncol; 2009 Nov; 115(2):249-56. PubMed ID: 19692115
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Uterine papillary serous carcinoma: comparisons of outcomes in surgical Stage I patients with and without adjuvant therapy.
    Huh WK; Powell M; Leath CA; Straughn JM; Cohn DE; Gold MA; Falkner CA; Carey DE; Herzog T; Fowler JM; Partridge EE; Kilgore LC; Alvarez RD
    Gynecol Oncol; 2003 Dec; 91(3):470-5. PubMed ID: 14675664
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patterns of relapse in stage I-II uterine papillary serous carcinoma treated with adjuvant intravaginal radiation (IVRT) with or without chemotherapy.
    Desai NB; Kiess AP; Kollmeier MA; Abu-Rustum NR; Makker V; Barakat RR; Alektiar KM
    Gynecol Oncol; 2013 Dec; 131(3):604-8. PubMed ID: 24055615
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Survival advantage associated with multimodal therapy in women with node-positive (stage-IIIC) uterine papillary serous carcinoma: a National Cancer Database study.
    Lin JF; Muñiz K; Sukumvanich P; Gehrig P; Beriwal S; Kelley JL; Edwards RP; Olawaiye AB
    BJOG; 2016 Oct; 123(11):1846-52. PubMed ID: 26537059
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.